VXTR: Phase 2 Hit, But Long-Term Play Still Possible The Phase 2 miss stings, but biotech is all about the long haul. If VXTR can nail its oral flu vaccine or score a partnership, it might rebound. Not loading up yet, but it’s worth watching. Also, keeping an eye on BOLT—it’s getting a lot of buzz, and it could pop any day now.